Nucleus3 Revenue and Competitors

Melbourne, Australia

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Nucleus3's estimated annual revenue is currently $1.2M per year.(i)
  • Nucleus3's estimated revenue per employee is $87,000

Employee Data

  • Nucleus3 has 14 Employees.(i)
  • Nucleus3 grew their employee count by 17% last year.

Nucleus3's People

NameTitleEmail/Phone
1
Founder Nucleus3 / Chief Customer OfficerReveal Email/Phone
2
Operational Technology ConsultantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$22.5M1411%N/AN/A
#2
$1.4M16-11%$4MN/A
#3
$44M276-3%N/AN/A
#4
$91M5028%N/AN/A
#5
$79.8M4408%N/AN/A
#6
$14.9M1036%N/AN/A
#7
$38.1M2395%$2MN/A
#8
$9.7M74-1%N/AN/A
#9
$8M61-13%N/AN/A
#10
$29.5M1858%N/AN/A
Add Company

What Is Nucleus3?

Nucleus3 is an organisation that focuses on delivering the outcomes for customer-centric organisations, We provide the flexibility of local, offshore and a blended delivery models that allows our customers to structure their programs of work to meet their time-frames and business objectives. We have established a strong team of consultants who have extensive industry experience and a strong focus on: ICT - Enterprise Architecture, Solution Design Program Management - Program Directors/Managers and Project Managers Program Support - Business Analysts and Technical Writers Business Advisory - Business and Management Consultancy Asset Management - operational / asset technology Smart Grid and IoT technologies - Advisory and Support

keywords:N/A

N/A

Total Funding

14

Number of Employees

$1.2M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nucleus3 News

2022-03-22 - AstraZeneca – Advances in Epigenetics in Oncology

... that is wound around histone proteins and packaged into chromatin, providing an efficient way to organise DNA in the nucleus.3 However,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.2M1417%N/A
#2
$1.2M14-26%N/A
#3
$1.2M1417%N/A
#4
$2.4M14-18%N/A
#5
$0.9M14-7%N/A